분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2012-12-22 17:22:12 , Hit : 2485
 Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty

December 19, 2012 6:41 pm by Stephanie Baum | 0 Comments


In one of the largest financing rounds this year, biopharmaceutical startup Regado Biosciences has raised $51 million to advance its anti-clotting therapeutic through Phase 3 clinical trials.

A subsidiary of Russian investment firm Rusnano,RusnanoMedInvest, led the Series E round. Baxter Ventures, part of Baxter Healthcare, also was a firsttime investor in the company., according to a company statement. Existing investors participating in the round included Edmond de Rothschild Investment Partners, Domain Associates, Quaker Partners, Aurora Funds and Caxton Advantage Life Sciences Fund also participated in the round.

Its lead treatment is REG 1, a therapeutic consisting of an aptamer paired with an active control agent. Aptamers, developed in vitro, have been likened to antibodies because of their binding affinity for their targets. The treatment’s lead indication is to control bleeding in coronary angioplasty procedures. The Basking Ridge, New Jersey biopharmaceutical startup is also pursuing a parallel indication for the therapeutic for use in open heart surgery.

Other treatment programs in its pipeline that will benefit from the new funding include its REG1 indication for transaortic valve implantation and its treatment for diabetic vasculopathy, a blood vessel disorder, expected to begin Phase 1 clinical trials in 2013.

The Phase 3 trial will look at the efficacy of the therapeutic. Patients will be enrolled at about 500 sites and it is expected to be completed two years after it begins.


Read more: http://medcitynews.com/2012/12/biopharma-startup-raises-51m-for-therapeutic-to-treat-bleeding-complications-from-angioplasty/#ixzz2Flc9jvPM







  Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty  이성욱 2012/12/22 2485
686   술 퍼먹게 하는 유전자 있다  이성욱 2012/12/07 2834
685   Glybera Gains Official EMA Nod as First Gene Therapy  이성욱 2012/11/06 2637
684   Genomics: The single life  이성욱 2012/11/06 2086
683   CU-Boulder researchers uncover new target for cancer research  이성욱 2012/11/06 2705
682   유럽 첫 유전자 치료제 승인 지단백 리파제 결핍약 '글리베라' 허가  이성욱 2012/11/06 3922
681   Whitehead scientists identify major flaw in standard approach to global gene expression analysis  이성욱 2012/10/29 2200
680   Nobel work boosts drug development  이성욱 2012/10/23 2526
679   유도만능줄기세포, 진짜 만능일까?  이성욱 2012/10/17 2667
678   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2530
677   Smallest and fastest-known RNA switches provide new drug targets  이성욱 2012/10/11 2447
676   The Nobel Prize in Physiology or Medicine 2012  이성욱 2012/10/09 2536
675   日 교토대, 쥐 유도만능줄기세포로 난자 만들어  이성욱 2012/10/06 3094
674   “몸매는 날씬해야” 강박관념도 유전자 탓  이성욱 2012/10/04 2634
673   유전자 요법의 후각기능 회복  이성욱 2012/09/12 3083
672   인간 게놈 백과사전 완성: 게놈은 유전자의 단순한 집합체가 아니다  이성욱 2012/09/10 2715
671   자궁경부 암 발생에서 HPV E7의 역할  이성욱 2012/09/10 3644
670   Scientists Design Molecule That Reverses Some Fragile X Syndrome Defects  이성욱 2012/09/07 2527
669   잠 못자는 당신, 알츠하이머병 초기증상?  이성욱 2012/09/07 3618
668   게놈 99% 정크 DNA ‘스위치 역할’  이성욱 2012/09/06 2667

[이전 10개] [1]..[21][22][23][24][25][26][27][28][29] 30 ..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN